



Published in final edited form as:

Oral Oncol. 2016 August ; 59: 58–66. doi:10.1016/j.oraloncology.2016.05.014.

Unraveling the Oral Cancer lncRNAome: Identification of Novel lncRNAs Associated with Malignant Progression and HPV Infection

Nijiro Nohata^a, Martin C. Abba^b, and J. Silvio Gutkind^{a,c,*}

^aMoore's Cancer Center, University of California, San Diego, La Jolla, California

^bCINIBA, CONICET, School of Medical Sciences, National University of La Plata, La Plata, Argentina

^cDepartment of Pharmacology, University of California, San Diego, La Jolla, California

Abstract

Objectives—The role of long non-coding RNA (lncRNA) expression in human head and neck squamous cell carcinoma (HNSCC) is still poorly understood. In this study, we aimed at establishing the onco-lncRNAome profiling of HNSCC and to identify lncRNAs correlating with prognosis and patient survival.

Materials and Methods—The Atlas of Noncoding RNAs in Cancer (TANRIC) database was employed to retrieve the lncRNA expression information generated from The Cancer Genome Atlas (TCGA) HNSCC RNA-sequencing data. RNA-sequencing data from HNSCC cell lines were also considered for this study. Bioinformatics approaches, such as differential gene expression analysis, survival analysis, principal component analysis, and Co-lncRNA enrichment analysis were performed.

Results—Using TCGA HNSCC RNA-sequencing data from 426 HNSCC and 42 adjacent normal tissues, we found 728 lncRNA transcripts significantly and differentially expressed in HNSCC. Among the 728 lncRNAs, 55 lncRNAs were significantly associated with poor prognosis, such as overall survival and/or disease-free survival. Next, we found 140 lncRNA transcripts significantly and differentially expressed between Human Papilloma Virus (HPV) positive tumors and HPV negative tumors. Thirty lncRNA transcripts were differentially expressed between *TP53* mutated and *TP53* wild type tumors. Co-lncRNA analysis suggested that protein-coding genes that are co-expressed with these deregulated lncRNAs might be involved in cancer associated molecular events. With consideration of differential expression of lncRNAs in a

*Corresponding author; J. Silvio Gutkind, Ph.D., Present/permanent address; 3855 Health Sciences Drive #0803, La Jolla, CA 92093-0803 Phone: +1 (858) 534-5980; sgutkind@ucsd.edu.

CONFLICT OF INTEREST

No conflicts of interest with the contents of this article.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

HNSCC cell lines panel (n=22), we found several lncRNAs that may represent potential targets for diagnosis, therapy and prevention of HNSCC.

Conclusion—LncRNAs profiling could provide novel insights into the potential mechanisms of HNSCC oncogenesis.

Keywords

Long non-coding RNA; RNA-sequencing; head and neck squamous cell carcinoma (HNSCC); human papilloma virus (HPV); TP53; TCGA

INTRODUCTION

More than 59,000 new cases of head and neck cancers are estimated for 2015 in the US alone, including 45,000 cases arising in the oral cavity and pharynx and 13,000 in the larynx, resulting each year in approximately 11,000 cancer-associated deaths (<http://seer.cancer.gov/>). Most head and neck malignancies are squamous cell carcinoma (HNSCC), which remain associated with a poor outcome [1], primarily due to local tumor recurrence and regional lymph node and distant metastasis, despite of considerable advances in multimodality therapy including surgery, radiation therapy and chemotherapy to control local disease [2]. Therefore, understanding the molecular mechanisms underlying HNSCC could help to improve diagnosis, and facilitate the development of new strategies to treat and prevent this disease.

The non-coding regions of the human genome were previously considered as the “junk” or “noise” [3]. However, along with the advance of comprehensive sequencing and high resolution microarray technologies, it has been demonstrated that 98% of the human genome is part of the non-coding region [4]. Approximately 70% of the genome is actively transcribed according to the ENCODE project [5]. The proportion of non-coding sequences that are actively transcribed increases with eukaryotes complexity [6]. Therefore, understanding the non-coding RNAs (ncRNAs) world has become essential. ncRNAs are classified broadly into two groups based on the size of the transcript: short ncRNAs (<200nt) and long ncRNAs (lncRNAs) (>200nt). The group of short ncRNA including microRNA (miRNA), piwi-interacting RNA (piRNA), and small interfering RNA (siRNA) has attracted considerable attention in the last few years, as miRNAs, for example, play important regulatory roles in cancer and other diseases [7-9].

LncRNAs are generally defined as endogenous non-coding RNA molecules longer than 200nt in length. To date 14,880 lncRNAs from 9,277 loci have been annotated by the GENCODE project [10]. Most of lncRNAs are transcribed by RNA polymerase II, then polyadenylated and pre-RNA spliced. The majority of lncRNAs are located in cell nucleus, but some of lncRNAs are in both nucleus and cytoplasm, and some lncRNAs locate to the cytoplasm specifically. Their expression patterns are highly tissue-specific [11], with lncRNA expression generally lower than that for mRNA [12].

LncRNAs are classified based on their genomic position related with neighboring genes (e.g. intergenic, exonic, intronic or overlapping genes) and also based on their structural or

functional features (e.g., circular RNAs, antisense RNAs, transcribed ultraconserved noncoding RNAs (T-UCRs), long enhancer ncRNAs, long intergenic ncRNAs (lincRNAs) and pseudogenes) [10,13]. LncRNAs are involved in diverse biological processes [14]. They can negatively or positively affect expression of protein-coding gene by transcriptional interference or by chromatin modification. For example, antisense transcripts can hybridize to their specific pre-mRNAs resulting in alternatively spliced mRNAs or generating endogenous siRNAs through Dicer [15]. LncRNAs can silence miRNA expression as “miRNA sponges” [16]. They can also modulate protein activity and cellular localization [14]. Moreover, lincRNAs can be processed to small ncRNAs that may act as endo-siRNAs or miRNAs [17]. Ultimately, lincRNAs are involved in multiple structural and/or organizational roles in the cell, and emerging reports indicate that lincRNAs are dysregulated in various diseases [18,19]. Although the complexity of the biological functions of lincRNAs are still mostly unknown, accumulating studies suggest that lincRNAs contribute to the initiation and development of various cancer types by acting as oncogenic or tumor suppressive RNAs [20-24].

While in the past genetic analyses in HNSCC had been often performed in small cohorts of patients in single platforms, the recent availability of large publically available cancer data sets enabled by the TCGA (The Cancer Genome Atlas), has revolutionized cancer biology as we know it [25]. TCGA was launched in 2006, as part of a coordinated effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH) in the United States (<http://cancergenome.nih.gov/abouttcga>). TCGA is a comprehensive project aimed at increasing the understanding of the molecular mechanism of cancer through the use of multiple platform technologies, including large-scale genome sequencing, in clinically annotated cancer specimens. This integrated genomic analysis has accelerated the discovery and validation of novel molecular mechanisms driving cancer progression in multiple cancer types. In this context, the TCGA project team has recently published the comprehensive genomic analysis of HNSCC from 279 patients [26].

In this study, we investigated deregulated expression of lincRNAs during HNSCC progression by analyzing the emerging sequence information from normal and HNSCC cancer lesions in the TCGA databases. This HNSCC lincRNAome profiling revealed remarkable tissue specificity of lincRNA expression in both normal and malignant tissues, and that HPV status and genomic alterations affect the lincRNA expression patterns. These results might provide a new avenue for diagnosis and therapeutic intervention in HNSCC.

MATERIALS AND METHODS

Data retrieval of lincRNA profiles from HNSCC cancer cell lines and clinical samples

We used The Atlas of Noncoding RNAs in Cancer (TANRIC) [27] to retrieve the lincRNA expression information from the TCGA HNSCC RNA-sequencing database. After retrieving the data, we annotated each of the samples according to their barcode ID based on the available clinical information, including overall survival (OS), disease-free survival (DFS) status, clinical stage, the HPV infection status, and the presence of gene mutations in HNSCC-relevant genes, such as *TP53*, and *PIK3CA* from cBioPortal [28]. Patient and tissue

sample characteristics are described in Supplementary Table 1. The procedure of RNA-sequencing profiling from a large panel of HNSCC-derived cells from different anatomical locations and human papillomavirus (HPV) infection status (herein referred as oral and pharyngeal cancer; OPC-22 panel) was previously described [29].

Statistical and data mining analyses of lncRNA profiles among HNSCC

We utilized the SAM test to identify differentially expressed lncRNAs among normal and HNSCC and additional factors such as: HPV infection and *TP53* mutation. Statistical analysis and heatmap visualization of differentially expressed transcripts were done with the MultiExperiment Viewer software (MeV 4.9) [30].

To further explore the prognostic value of the lncRNAs in HNSCC, a group of 418 patients with HNSCC for OS or 301 out of 418 patients with HNSCC for DFS with follow-up data were divided in two subgroups according to the median expressions of each lncRNA analyzed. These groups were then analyzed by univariate (Kaplan–Meier survival curves and log-rank statistics) and multivariate (Cox proportional hazards) methods using the Survival R package. The multivariate Cox proportional-hazard model included: gender, anatomic location, tumor pathological stage, *TP53* mutation status and gene expression of the lncRNA under consideration. In this model, HPV infection was not included because of the limited number of samples with HPV infection data. Overall survival and disease-free survival were the end points.

The Co-LncRNA online resource was employed to identify bioprocess modulated by lncRNAs. Briefly, Co-LncRNA is a web-based tool that performs Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses based on co-expressed protein-coding genes (CEGs) of a single or multiple lncRNAs [31]. The REViGO resource was employed to summarize and visualize the enriched GO terms in a scatterplot graph based on the corrected p-values obtained by Co-LncRNA resource [32].

RESULTS

Differential expression and prognosis associated lncRNAs in Tumor vs. Normal analysis

First, we employed the data from 468 HNSCC samples in TCGA RNA-sequencing data generated by Illumina HiSeq 2000. Statistical analysis of lncRNA profiles revealed 728 transcripts differentially expressed between normal and tumor samples (212 up-modulated and 516 down-modulated lncRNAs). The most statistically significant transcripts deregulated between normal and tumor samples are represented in Figure 1B, and all relevant information can be found in Supplementary Table 2 (using a cutoff of absolute fold-change > 1.5 and q-value < 0.001). Sub-organ specifically expressed lncRNAs are also shown in Figure 1A and described in Supplementary table 2. GO enrichment analysis for protein-coding genes that are co-expressed with the deregulated lncRNAs was performed by the Co-LncRNA algorithm [31], which identifies CEGs that are significantly related to gene expression, RNA splicing, protein metabolism, Tie/Notch/Wnt pathways, apoptosis, cell cycle, endocytosis, and trafficking activities, which were summarized and visualized by REViGO approach (Figure 1C and Supplementary table 2).

We found 55 lncRNAs which have significant relationship with patient's prognosis in OS or DFS (log-rank test p-value < 0.05) among 728 deregulated lncRNAs (Supplementary Table 2). To further evaluate the independent prognostic value of these 55 lncRNAs, we next performed a multivariate Cox proportional-hazard analysis that included the traditional prognostic factors such as: tumor pathological stage, anatomic location, *TP53* mutation status and gender. This analysis demonstrated that 23 out of 55 lncRNAs were independent predictors of overall survival (Supplementary Table 2).

Representative genes are listed in Table 1. Kaplan-Meier plots of representative prognosis-associated lncRNAs are shown in Figure 2A. KEGG pathway enrichment analysis based on Co-LncRNA algorithm for the protein-coding genes which are co-expressed with the prognosis associated lncRNAs suggests that those CEGs are significantly linked to several oncogenic events, such as cell cycle, spliceosome, endocytosis, regulation of actin cytoskeleton, MAPK, Wnt, VEGF, Neutrophin, Insulin, ERBB, and Notch signaling (Figure 2B). Among these 728 lncRNAs, eight lncRNA genes (*ADAMTS9-AS2*, *CBR3-AS1*, *DLEU2*, *FGF10-AS1*, *HCP5*, *LINC00271*, *PDZRN3-AS1*, *RMST*, *TUG1*, *TUSC8*) were matched with the list of LncRNADisease database [33], which are lncRNAs previously reported in relationship with disease including several malignancies (Supplementary Table 3). We briefly summarize the current knowledge of these genes in the discussion section.

Differential expression in HNSCC cell lines and HPV-specific lncRNAs

Recently, we have performed the full exome and transcriptome sequencing of OPC-22 panel [29]. Principal component analysis (PCA) showed that the cluster of NOKSI (normal oral keratinocyte spontaneously immortalized) as a control was clearly different from that of HNSCC cell lines (Figure 3A). Aberrantly expressed 30 lncRNAs in both HNSCC cell lines and tumor tissues in TCGA were shown as colored dots in volcano plots by $p < 0.05$ (Figure 3B and Supplementary Table 4). The role of HPV on lncRNA expression in HNSCC is largely unknown. Hence, we used the opportunity to analyze the differential expression profile between HPV positive (HPV+) and HPV negative (HPV-) HNSCC cells in the OPC-22 panel, and HPV+ and HPV- HNSCC tumors in TCGA. In the OPC-22 panel, PCA shows distinct position of component among control, HPV+, and HPV- cells (Figure 3A). There were 27 upregulated lncRNAs in HPV+ cells by absolute fold-change > 1.5, and $q < 0.001$ (Figure 3C). Among them, *LINC01305*, *LINC01089*, and *PTOV1-AS1* were also significantly up-modulated in HPV+ tumor samples in TCGA. Overall, there were 140 up-modulated lncRNAs in HPV+ tumors in TCGA by absolute fold-change > 1.5, and $q < 0.001$ (Figure 3D, and supplementary table 5).

Differential lncRNA expression depending on *TP53* gene mutation status in HNSCC

Alterations in *TP53* gene are particularly of relevance in HNSCC with regards to tobacco carcinogens and HPV-infection [34]. Most HNSCC cases associated with tobacco use harbor *TP53* mutations, while most HPV+ HNSCC exhibit wild type *TP53*. There were 30 down-modulated lncRNAs in *TP53* mutated (non-silent mutation curated by Broad Institute) tumors compared with *TP53* wild type tumors by absolute fold-change > 1.5, and $q < 0.001$ (Figure 4A, 4C and Supplementary table 6). Among the 30 lncRNAs, 19 transcripts are associated with HPV+ tumors (Figure 4B). KEGG pathway enrichment analysis based on

Co-LncRNA algorithm for the protein-coding genes which are co-expressed with the *TP53* mutation-associated lncRNAs surprisingly indicated that these protein-coding genes were significantly related to p53-regulated signaling pathways (Figure 4D).

DISCUSSION

Recently, a growing body of evidence indicates that lncRNAs are associated with diverse and essential functions in cell biology [35]. Previous studies on lncRNAs in HNSCC have been focused on known cancer-related transcripts. For example, *HOTAIR* was found to be upregulated in laryngeal squamous cell carcinoma (SCC) when compared to adjacent normal tissues. There was a significant association between high levels of *HOTAIR* and poor prognosis in laryngeal SCC patients. Furthermore, *HOTAIR* regulates DNA methylation at the *PTEN* promoter, which leads to decreased expression of the tumor suppressor, *PTEN* [36]. Similarly, *UCA-1*, *MALAT-1*, *NEAT-1*, *MEG3* [37-39], and *GAS5* [40] were previously reported as dysregulated in HNSCC. In this regard, to further clarify the global expression of lncRNAs in this cancer type, we investigated the lncRNA expression signatures in the emerging TCGA HNSCC RNA-sequencing information [27] and in a wide variety of HNSCC cell lines [29]. Of interest, we failed to identify those previously mentioned transcripts as differentially expressed across our large (more than 400 cases) cohort, which was similar to the recent study in which a comprehensive analysis of lncRNAs expression was conducted in multiple HNSCC cases [41]. Thus, some lncRNA subsets previously identified in small sample collections are likely of direct relevance to the particular local risk factors or genetic variations, but not to the general aspects of HNSCC pathophysiology in the overall patient population. Here, we successfully found a number of novel lncRNAs which were associated with HNSCC oncogenesis and progression.

Overall, we found 516 upregulated and 212 downregulated lncRNAs in HNSCC samples based on 12,727 lncRNAs already registered in the TANRIC database [27]. Among the 728 lncRNAs, some lncRNAs have been documented to be associated with human diseases, including malignancies (Supplementary table 3). For example, *TUG1* acts as an oncogene through promoting cell proliferation of esophageal SCC [42], bladder cancer [43], hepatocellular carcinoma (HCC) [44], and osteosarcoma [45]. *TUG1* expression has been reported to be regulated by p53 in non-small cell lung carcinoma (NSCLC) [46] and SP1 transcription factor in HCC [44]. *CBR3-AS1* (also known as *PlncRNA-1*) expression was significantly higher in prostate cancer cells relative to normal prostate epithelial cells, as well as higher in human prostate cancer tissues compared with normal tissues and benign prostatic hyperplasia [47]. The expression of *CBR3-AS1* was also upregulated in human esophageal SCC compared with the adjacent noncancerous tissues [48]. However, in our current result, *CBR3-AS1* was significantly downregulated in HNSCC tumor tissues. Probably, those differences might be due to a cancer type specific expression. *ADAMTS9-AS2*, which was down-modulated in HNSCC tumors, was reported as a new tumor suppressive lncRNA regulated by DNA-Methyltransferase 1 (DNMT1) in glioma [49]. *TUSC8 (XLOC_010588)* expression was significantly downregulated in cervical cancer [50], and it was consistently down-modulated in HNSCC tumors.

We identified 55 prognosis-associated lncRNAs in the HNSCC TCGA, and among them, the expression of 23 transcripts were independently associated with overall risk of death in HNSCC patients regardless of gender, organ site, tumor pathological stage, and *TP53* gene mutation status. Our enrichment analysis indicates that those lncRNAs are co-expressed with protein-coding genes involved in several oncogenic signaling pathways. This suggests that these lncRNAs might play important and functional roles by regulating directly or indirectly key protein-coding gene expression that in turn may contribute to HNSCC. For example, *CASC9 (ESCCAL-1)*, which we identified in our analysis of HNSCC, was also overexpressed in esophageal SCC, where it functions as an onco-lncRNA through inhibition of apoptosis and promoting invasion *in vitro* [51].

We also focused on the common deregulated lncRNAs in both HNSCC TCGA and OPC-22 panel. Among the thirty aberrantly expressed transcripts, *FIRRE (Functional Intergenic Repeating RNA Element)* was found to be up-modulated in both tumor samples and HNSCC cell lines. Recently, *FIRRE* was reported to interact with the nuclear matrix factor hnRNPU [52]. *FIRRE* localizes across at least three distinct *trans*-chromosomal loci. Both genomic excision of *FIRRE* locus and knockdown of *hnRNPU* shows decreased co-localization of these *trans*-chromosomal interacting loci [52]. Thus, aberrant epigenetic alterations caused by deregulated *FIRRE* levels may represent a novel HNSCC oncogenic mechanism, which should be clarified in future experimental studies.

The role of HPV infection on lncRNA expression in HNSCC remains unclear. To the best of our knowledge, our analysis provides the first evidence of the existence of a differential expression profile based on the HPV infection status using both HNSCC cell lines (OPC-22 panel) and clinical samples from the TCGA HNSCC. HPV+ tumors were predominantly from pharyngeal site (80.8%) and did not exhibit mutated *TP53*, whereas HPV- tumors were mostly located in the oral and larynx (91.0%), and frequently harbor *TP53* mutations (95%), as expected [53] (Figure 4A). Several lncRNAs are commonly deregulated in both cell lines and clinical samples, such as *LINC01305*, *LINC01089*, and *PTOV1-AS1*. There have been no detailed reports of those lncRNAs so far. The studies exploring the biological relevance and interplay between HPV infection and lncRNAs are still quite few [54,55].

TP53 mutations are the most frequent mutations in HNSCC [26,53]. We also conducted differential expression analysis between *TP53* non-silent mutated tumors and *TP53* wild type tumors. There were 30 down-modulated lncRNAs in *TP53* mutated tumors. Among those lncRNAs, 19 lncRNAs were specifically expressed in HPV+ and *TP53* wild type tumors, suggesting that these lncRNAs are potential key molecules and that their study may provide novel insights into the mechanism of HPV-associated HNSCC oncogenesis. Recently, a growing number of studies have demonstrated that lncRNAs indeed act as functional components of the p53 pathway [56]. For example, tumor suppressive lncRNA, *MEG3* directly interacts with p53, and activates several p53-dependent gene transcripts [57]. p53 enhances the expression of *LINC-ROR* through a direct transcriptional activation. In turn, cytoplasmic-enriched *LINC-ROR* post-transcriptionally controls *TP53* levels by sequestering hnRNP I protein and inhibiting p53 translation [58]. *TUG1* has been identified as a p53 effector that is induced in response to DNA damage to mediate the inhibition of cell cycle genes [46]. Of interest, *LINC00925*, and *LINC01315* are especially co-expressed with

genes associated with p53 signaling pathways, suggesting these lncRNAs might be involved in p53 post-translational alteration and/or p53 downstream pathways. *PIK3CA* is also frequently mutated in HNSCC [26,53,59]. Although we performed differential gene expression analysis based on *PIK3CA* mutation status, no differentially expressed lncRNAs were identified in this study.

Recent studies suggest that lncRNAs are potential markers of cancer and might be helpful in the evaluation of diagnosis, classification, prognosis and distinct therapeutic strategies. In this analysis, we identified 317 lncRNAs that are expressed differentially between HNSCC tumors and normal samples, and 140 lncRNAs that differed between HPV positive tumors and HPV negative tumors. Further investigation may clarify the mechanisms underlying these differences, as well as how the changes in the HNSCC onco-lncRNAome contributes to the initiation and progression of this highly prevalent human malignancy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was partially supported by the Intramural Research Program of the National Institutes of Health, National Institute of Dental and Craniofacial Research (Project: Z01DE000558), and by funds provided by the UCSD Moores Cancer Center, Office of the Dean, Medical School, UCSD (JSG), and Instituto Nacional del Cáncer, Ministerio de Salud, Argentina (MCA).

References

- Haddad RI, Shin DM. Recent advances in head and neck cancer. *N Engl J Med*. 2008; 359:1143–54. DOI: 10.1056/NEJMra0707975 [PubMed: 18784104]
- Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. *Nat Rev Cancer*. 2011; 11:9–22. DOI: 10.1038/nrc2982 [PubMed: 21160525]
- Struhl K. Transcriptional noise and the fidelity of initiation by RNA polymerase II. *Nat Struct Mol Biol*. 2007; 14:103–5. DOI: 10.1038/nsmb0207-103 [PubMed: 17277804]
- Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet*. 2009; 10:155–9. DOI: 10.1038/nrg2521 [PubMed: 19188922]
- Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. *Nature*. 2012; 489:101–8. DOI: 10.1038/nature11233 [PubMed: 22955620]
- Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. *J Pathol*. 2010; 220:126–39. DOI: 10.1002/path.2638 [PubMed: 19882673]
- Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. *Cell*. 2012; 148:1172–87. DOI: 10.1016/j.cell.2012.02.005 [PubMed: 22424228]
- Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. *J Clin Invest*. 2013; 123:11–8. DOI: 10.1172/JCI62876 [PubMed: 23281405]
- Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol Med*. 2014; 20:460–9. DOI: 10.1016/j.molmed.2014.06.005 [PubMed: 25027972]
- Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012; 22:1775–89. DOI: 10.1101/gr.132159.111 [PubMed: 22955988]
- Mercer TR, Dinger ME, Sunkin SM, Mehler MF, Mattick JS. Specific expression of long noncoding RNAs in the mouse brain. *Proc Natl Acad Sci U S A*. 2008; 105:716–21. DOI: 10.1073/pnas.0706729105 [PubMed: 18184812]

12. Yang J-R, Zhang J. Human long noncoding RNAs are substantially less folded than messenger RNAs. *Mol Biol Evol.* 2015; 32:970–7. DOI: 10.1093/molbev/msu402 [PubMed: 25540450]
13. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nat Rev Drug Discov.* 2013; 12:847–65. DOI: 10.1038/nrd4140 [PubMed: 24172333]
14. Geisler S, Collier J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat Rev Mol Cell Biol.* 2013; 14:699–712. DOI: 10.1038/nrm3679 [PubMed: 24105322]
15. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. *Genes Dev.* 2009; 23:1494–504. DOI: 10.1101/gad.1800909 [PubMed: 19571179]
16. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. *Curr Biol.* 2010; 20:R858–61. DOI: 10.1016/j.cub.2010.08.052 [PubMed: 20937476]
17. Röther S, Meister G. Small RNAs derived from longer non-coding RNAs. *Biochimie.* 2011; 93:1905–15. DOI: 10.1016/j.biochi.2011.07.032 [PubMed: 21843590]
18. Clark MB, Mattick JS. Long noncoding RNAs in cell biology. *Semin Cell Dev Biol.* 2011; 22:366–76. DOI: 10.1016/j.semcdb.2011.01.001 [PubMed: 21256239]
19. Wapinski O, Chang HY. Long noncoding RNAs and human disease. *Trends Cell Biol.* 2011; 21:354–61. DOI: 10.1016/j.tcb.2011.04.001 [PubMed: 21550244]
20. Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. *Br J Cancer.* 2013; 108:2419–25. DOI: 10.1038/bjc.2013.233 [PubMed: 23660942]
21. Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. *Int J Biochem Cell Biol.* 2013; 45:1895–910. DOI: 10.1016/j.biocel.2013.05.030 [PubMed: 23748105]
22. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. *Cancer Lett.* 2013; 339:159–66. DOI: 10.1016/j.canlet.2013.06.013 [PubMed: 23791884]
23. Kunej T, Obsteter J, Pogacar Z, Horvat S, Calin GA. The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. *Crit Rev Clin Lab Sci.* 2014; 51:344–57. DOI: 10.3109/10408363.2014.944299 [PubMed: 25123609]
24. Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. *Biochim Biophys Acta.* 2014; 1839:1097–109. DOI: 10.1016/j.bbagr.2014.08.012 [PubMed: 25159663]
25. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. *Nature.* 2014; 505:495–501. DOI: 10.1038/nature12912 [PubMed: 24390350]
26. The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature.* 2015; 517:576–82. DOI: 10.1038/nature14129 [PubMed: 25631445]
27. Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, et al. TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. *Cancer Res.* 2015; 75:3728–37. DOI: 10.1158/0008-5472.CAN-15-0273 [PubMed: 26208906]
28. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal.* 2013; 6:pl1.doi: 10.1126/scisignal.2004088 [PubMed: 23550210]
29. Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, et al. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. *Oncotarget.* 2014; 5:8906–23. [PubMed: 25275298]
30. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. *Biotechniques.* 2003; 34:374–8. [PubMed: 12613259]
31. Zhao Z, Bai J, Wu A, Wang Y, Zhang J, Wang Z, et al. Co-LncRNA: investigating the lncRNA combinatorial effects in GO annotations and KEGG pathways based on human RNA-Seq data. *Database (Oxford).* 2015; 2015doi: 10.1093/database/bav082
32. Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. *PLoS One.* 2011; 6:e21800.doi: 10.1371/journal.pone.0021800 [PubMed: 21789182]

33. Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. *Nucleic Acids Res.* 2013; 41:D983–6. DOI: 10.1093/nar/gks1099 [PubMed: 23175614]
34. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. *Oral Oncol.* 45:324–34. DOI: 10.1016/j.oraloncology.2008.07.011
35. Quinodoz S, Guttman M. Long noncoding RNAs: an emerging link between gene regulation and nuclear organization. *Trends Cell Biol.* 2014; 24:651–63. DOI: 10.1016/j.tcb.2014.08.009 [PubMed: 25441720]
36. Li D, Feng J, Wu T, Wang Y, Sun Y, Ren J, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. *Am J Pathol.* 2013; 182:64–70. DOI: 10.1016/j.ajpath.2012.08.042 [PubMed: 23141928]
37. Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H. Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2014; 117:89–95. DOI: 10.1016/j.oooo.2013.09.007 [PubMed: 24332332]
38. Tang H, Wu Z, Zhang J, Su B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. *Mol Med Rep.* 2013; 7:761–6. [PubMed: 23292713]
39. Feng J, Tian L, Sun Y, Li D, Wu T, Wang Y, et al. Expression of long non-coding ribonucleic acid metastasis-associated lung adenocarcinoma transcript-1 is correlated with progress and apoptosis of laryngeal squamous cell carcinoma. *Head Neck Oncol.* 2012; 4:46.
40. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. *Br J Cancer.* 2011; 104:1168–77. DOI: 10.1038/sj.bjc.6606076 [PubMed: 21407217]
41. Zou AE, Ku J, Honda TK, Yu V, Kuo SZ, Zheng HaO, et al. Transcriptome sequencing uncovers novel long noncoding and small nucleolar RNAs dysregulated in head and neck squamous cell carcinoma. *Rna.* 2015; 21:1–13. DOI: 10.1261/rna.049262.114.4 [PubMed: 25516996]
42. Xu Y, Wang J, Qiu M, Xu L, Li M, Jiang F, et al. Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma. *Tumour Biol.* 2015; 36:1643–51. DOI: 10.1007/s13277-014-2763-6 [PubMed: 25366138]
43. Han Y, Liu Y, Gui Y, Cai Z. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. *J Surg Oncol.* 2013; 107:555–9. DOI: 10.1002/jso.23264 [PubMed: 22961206]
44. Huang M-D, Chen W-M, Qi F-Z, Sun M, Xu T-P, Ma P, et al. Long non-coding RNA TUG1 is up-regulated in hepatocellular carcinoma and promotes cell growth and apoptosis by epigenetically silencing of KLF2. *Mol Cancer.* 2015; 14:165.doi: 10.1186/s12943-015-0431-0 [PubMed: 26336870]
45. Zhang Q, Geng P-L, Yin P, Wang X-L, Jia J-P, Yao J. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis. *Asian Pac J Cancer Prev.* 2013; 14:2311–5. [PubMed: 23725133]
46. Zhang E, Yin D, Sun M, Kong R, Liu X, You L, et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. *Cell Death Dis.* 2014; 5:e1243.doi: 10.1038/cddis.2014.201 [PubMed: 24853421]
47. Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y, et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. *Urol Oncol.* 2013; 31:1117–23. DOI: 10.1016/j.urolonc.2011.11.030 [PubMed: 22264502]
48. Wang C-M, Wu Q-Q, Li S-Q, Chen F-J, Tuo L, Xie H-W, et al. Upregulation of the long non-coding RNA PlncRNA-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. *Dig Dis Sci.* 2014; 59:591–7. DOI: 10.1007/s10620-013-2956-7 [PubMed: 24337686]

49. Yao J, Zhou B, Zhang J, Geng P, Liu K, Zhu Y, et al. A new tumor suppressor lncRNA ADAMTS9-AS2 is regulated by DNMT1 and inhibits migration of glioma cells. *Tumor Biol.* 2014; 35:7935–44. DOI: 10.1007/s13277-014-1949-2
50. Liao L-M, Sun X-Y, Liu A-W, Wu J-B, Cheng X-L, Lin J-X, et al. Low expression of long noncoding XLOC_010588 indicates a poor prognosis and promotes proliferation through upregulation of c-Myc in cervical cancer. *Gynecol Oncol.* 2014; 133:616–23. DOI: 10.1016/j.ygyno.2014.03.555 [PubMed: 24667250]
51. Hao Y, Wu W, Shi F, Dalmolin RJS, Yan M, Tian F, et al. Prediction of long noncoding RNA functions with co-expression network in esophageal squamous cell carcinoma. *BMC Cancer.* 2015; 15:168.doi: 10.1186/s12885-015-1179-z [PubMed: 25885227]
52. Hacisuleyman E, Goff LA, Trapnell C, Williams A, Henao-Mejia J, Sun L, et al. Topological organization of multichromosomal regions by the long intergenic noncoding RNA Firre. *Nat Struct Mol Biol.* 2014; 21:198–206. DOI: 10.1038/nsmb.2764 [PubMed: 24463464]
53. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. *Science.* 2011; 333:1157–60. DOI: 10.1126/science.1208130 [PubMed: 21798893]
54. Jiang Y, Li Y, Fang S, Jiang B, Qin C, Xie P, et al. The role of MALAT1 correlates with HPV in cervical cancer. *Oncol Lett.* 2014; 7:2135–41. DOI: 10.3892/ol.2014.1996 [PubMed: 24932303]
55. Sharma S, Mandal P, Sadhukhan T, Roy Chowdhury R, Ranjan Mondal N, Chakravarty B, et al. Bridging Links between Long Noncoding RNA HOTAIR and HPV Oncoprotein E7 in Cervical Cancer Pathogenesis. *Sci Rep.* 2015; 5:11724.doi: 10.1038/srep11724 [PubMed: 26152361]
56. Grossi E, Sánchez Y, Huarte M. Expanding the p53 regulatory network: lncRNAs take up the challenge. *Biochim Biophys Acta - Gene Regul Mech.* 2015; doi: 10.1016/j.bbagr.2015.07.011
57. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, et al. Activation of p53 by MEG3 non-coding RNA. *J Biol Chem.* 2007; 282:24731–42. DOI: 10.1074/jbc.M702029200 [PubMed: 17569660]
58. Zhang A, Zhou N, Huang J, Liu Q, Fukuda K, Ma D, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. *Cell Res.* 2013; 23:340–50. DOI: 10.1038/cr.2012.164 [PubMed: 23208419]
59. Lui VWY, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. *Cancer Discov.* 2013; 3:761–9. DOI: 10.1158/2159-8290.CD-13-0103 [PubMed: 23619167]

Abbreviations

HNSCC	Head and Neck Squamous Cell Carcinoma
HPV	Human Papilloma Virus
lncRNA	long non-coding RNA
TANRIC	The Atlas of Noncoding RNAs in Cancer
TCGA	The Cancer Genome Atlas

Highlights

- The oral cancer onco-lncRNAome was established by bioinformatics analysis.
- 728 deregulated lncRNAs were identified between tumor and normal tissues.
- 55 lncRNAs were associated with poor prognosis.
- 140 transcripts were found as deregulated lncRNAs between HPV+ and HPV-specimens.
- 30 lncRNAs were found deregulated between *TP53* mutated and *TP53* wild type tumors.




Figure 1. Differential expression analysis between tumor and normal tissues in the HNSCC TCGA. (A) Heatmap of 728 differentially expressed lncRNAs in comparison between tumor and normal tissues. (B) Representative differentially expressed lncRNAs between tumor and normal tissues. (C) Gene Ontology (GO) enrichment analysis for protein-coding genes co-expressed with 728 lncRNAs with visualization by REVIGO algorithm.




Figure 2. Overall survival (OS) and disease-free survival (DFS) plots and functional annotation of co-expressed protein-coding genes which are neighbor of 55 prognosis-associated lncRNAs. (A) Representative Kaplan-Meier plots were shown in OS (upper row), and DFS (lower row). (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis is shown in bar chart for protein-coding genes co-expressed with 55 prognosis-associated lncRNAs.




Figure 3. Differential expression analysis between HPV status in the OPC-22 panel and the TCGA HNSCC. (A) Principal component analysis (PCA) among NOKSI as control cells (green), HPV+ cells (blue) and HPV- cells (pink). (B) Volcano plots shows the means difference of expression in HNSCC cells vs. control cells in X axis, and significance in HNSCC cells vs. control cells in Y axis. Broken line indicates p-value < 0.05. (C) Heatmap of 27 differentially expressed lncRNAs in comparison between HPV+ and HPV- cells. LncRNAs in bold are commonly

up-modulated in HPV+ cells and tumors in TCGA HNSCC. (D) Heatmap of 140 differentially expressed lncRNAs in comparison between HPV+ and HPV- tumors in TCGA.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4.

Differential expression analysis based on *TP53* mutation status in the HNSCC TCGA.

(A) Heatmap of 42 differentially expressed lncRNAs in comparison between *TP53* mutation and *TP53* wild type. Sub organ site information (Pharynx: blue, Larynx: red, and Oral: green) and HPV infection status information (HPV+: dark gray, and HPV-: light blue) are included. (B) Venn diagram shows 19 overlapping up-modulated lncRNAs both in HPV+ and *TP53* wild type tumors. (C) Representative up-modulated lncRNAs in *TP53* wild type tumors are shown in bar chart. lncRNAs whose bars are in blue are significantly enriched in KEGG-P53 signaling pathway. (D) Co-expressed genes with *LINC01315* or *LINC00925* in KEGG-P53 signaling pathway (*LINC01315*: pink, and *LINC00925*: blue).

Table 1

Representative lncRNAs associated with poor prognosis among 55 lncRNAs.

ENSEMBL ID	Gene name	Fold change (Tumor/Normal)	Survival outcome	Log-rank p-value	Cox p-value	HR (95% CI)
<u>lncRNAs up-modulated in tumors</u>						
ENSG00000250874	CTC-480C2.1	148.6	Reduced OS	0.0006	0.1447	---
ENSG00000271127	LL22NC03-N64E9.1	24.4	Reduced OS	0.0247	0.0351	1.5 (1.03 – 2.27)
ENSG00000261327	RP11-863P13.3	18.5	Reduced DFS	0.0423	0.133	---
ENSG00000260162	RP11-863P13.1	17.1	Reduced DFS	0.015	0.0576	---
ENSG00000249395	CASC9	14.5	Reduced OS	0.0047	0.0498	1.5 (1 – 2.18)
ENSG00000256268	RP11-221N13.3	14.1	Reduced OS	0.0462	0.686	---
ENSG00000267284	RP11-397A16.1	12.4	Reduced OS	0.0109	0.0457	1.5 (1 – 2.23)
ENSG00000250546	RP11-8L2.1	11.2	Reduced OS	0.0213	0.1138	---
ENSG00000234695	AC002076.10	9.2	Reduced OS	0.0204	0.0285	1.5 (1.05 – 2.30)
ENSG00000225548	AC098973.2	8.8	Reduced OS	0.016	0.2062	---
ENSG00000234902	AC007879.2	5.7	Reduced OS	0.0009	0.1112	---
ENSG00000271826	PLS3-AS1	4.2	Reduced OS	0.019	0.5359	---
ENSG00000251381	LINC00958	3.5	Reduced OS	0.0139	0.3	---
ENSG00000237152	DLEU7-AS1	3	Reduced OS	0.0018	0.00348	1.8 (1.2 – 2.6)
ENSG00000230002	ALMS1-IT1	2.9	Reduced OS	0.0107	0.0102	1.7 (1.13 – 2.51)
ENSG00000245522	RP11-540A21.2	2.9	Reduced OS	0.0408	0.4654	---
ENSG00000232725	U52111.14	2.8	Reduced DFS	0.0432	0.21	---
ENSG00000254551	RP11-727A23.7	2.7	Reduced DFS	0.0203	0.306	---
ENSG00000259901	---	2.6	Reduced OS & DFS	<0.05	0.089 (OS) 0.542 (DFS)	---
ENSG00000172965	MIR4435-1HG	2.2	Reduced OS & DFS	<0.003	0.0955	---
<u>lncRNAs down-modulated in tumors</u>						
ENSG00000258616	RP11-369C8.1	-76.1	Increased DFS	0.0371	0.297	---
ENSG00000228789	HCG22	-21.9	Increased OS	0.002	0.2799	---
ENSG00000233987	AC106706.1	-21.1	Increased OS	0.0237	0.01534	0.41 (0.19 – 0.84)
ENSG00000231062	AC103563.9	-15.5	Increased OS	0.0127	0.0905	---
ENSG00000253389	RP11-930P14.1	-12.7	Increased OS	0.0388	0.09896	---
ENSG00000225129	RP4-614C15.2	-9.1	Increased OS	0.0101	0.0122	0.31 (0.12 – 0.77)

ENSEMBL ID	Gene name	Fold change (Tumor/Normal)	Survival outcome	Log-rank p-value	Cox p-value	HR (95% CI)
ENSG00000237530	RP3-449H6.1	-8.7	Increased OS	0.0093	0.05069	---
ENSG00000197585	AC107218.3	-8.1	Increased OS	0.0234	0.0238	0.62 (0.41 – 0.94)
ENSG00000259459	RP11-321G12.1	-8	Increased OS	0.0347	0.15003	---
ENSG00000260402	RP11-56L13.1	-7.4	Increased OS	0.0117	0.00206	0.54 (0.37 – 0.80)
ENSG00000223678	RP11-311H10.4	-6.8	Increased OS	0.0382	0.00528	0.45 (0.26 – 0.79)
ENSG00000266114	RP11-963H4.5	-6.5	Increased OS	0.0466	0.042	0.66 (0.45 – 0.98)
ENSG00000248799	CTC-548H10.2	-5.7	Increased OS & DFS	<0.05	0.8832 (OS) 0.182 (DFS)	---
ENSG00000249797	CTD-3179P9.1	-5.5	Increased OS	0.0059	0.00816	0.59 (0.39 – 0.87)
ENSG00000262133	RP11-676J12.6	-5	Increased OS	0.0343	0.916	---
ENSG00000232803	SLC04A1-AS1	-4.4	Increased DFS	0.0019	0.145	---
ENSG00000233070	ZFY-AS1	-4.3	Increased OS	0.0004	0.00389	0.50 (0.32 – 0.80)
ENSG00000233529	HCG21	-3.4	Increased OS	0.0108	0.1142	---
ENSG00000260931	---	-3.4	Increased OS	0.0035	0.01234	0.61 (0.41 – 0.90)
ENSG00000230790	AC012456.4	-3.3	Increased OS & DFS	<0.02	0.10733 (OS) 0.796 (DFS)	---

CI: Confidence interval
 DFS: Disease-free survival
 HR: Hazard ratio
 OS: Overall survival